# EDGAR Filing Document

**Accession Number:** 0001137360
**File Stem:** 0001752724-25-196060
**Filing Date:** 2025-8
**Character Count:** 15522
**Document Hash:** 3786c98773dbb79adf79c1615221a293
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-25-196060.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001752724-25-196060

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250821

**DATE AS OF CHANGE**: 20250821

**PERIOD START**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VanEck ETF Trust
- **CENTRAL INDEX KEY:** 0001137360

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-10325
- **FILM NUMBER:** 251239260

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-293-2000

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VanEck Vectors ETF Trust
- **DATE OF NAME CHANGE:** 20160427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS ETF TRUST
- **DATE OF NAME CHANGE:** 20070312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS TRUST
- **DATE OF NAME CHANGE:** 20050516

## Series and Classes Contracts Data

### VanEck Pharmaceutical ETF (Series ID: S000034409)

| Class ID   | Class Name                | Ticker Symbol   |
|:---|:---|:---|
| C000105867 | VanEck Pharmaceutical ETF | PPH             |

## Nport-Ex

VANECK

PHARMACEUTICAL

ETF

SCHEDULE

OF

INVESTMENTS

June

30,

2025

(unaudited)

#### FootnoteRuleAboveBlank

#### Footnotes:

#### Number

#### of

#### Shares

#### Value

#### COMMON

#### STOCKS:

#### 99.5%

#### Denmark

#### :

#### 7.5%
Novo

Nordisk

A/S

(ADR)

668,595

$

46,146,427

Underline

#### France

#### :

#### 4.5%
Sanofi

SA

(ADR)

568,627

27,470,370

Underline

#### Israel

#### :

#### 1.6%
Teva

Pharmaceutical

Industries

Ltd.

(ADR) \*

580,150

9,723,314

Underline

#### Japan

#### :

#### 3.0%
Takeda

Pharmaceutical

Co.

Ltd.

(ADR) †

1,176,822

18,193,668

Underline

#### Switzerland

#### :

#### 7.6%
Novartis

AG

(ADR)

384,207

46,492,889

Underline

#### United

#### Kingdom

#### :

#### 12.3%
AstraZeneca

PLC

(ADR)

383,248

26,781,371

GSK

PLC

(ADR) †

679,013

26,074,099

Haleon

PLC

(ADR) †

2,154,092

22,337,934

75,193,404

#### United

#### States

#### :

#### 63.0%
AbbVie,

Inc.

147,569

27,391,758

Axsome

Therapeutics,

Inc. \*

†

16,333

1,705,002

Bausch

Health

Cos,

Inc. \*

†

131,226

873,965

Bristol-Myers

Squibb

Co.

563,409

26,080,203

Cencora,

Inc.

79,067

23,708,240

#### Number

#### of

#### Shares

#### Value

#### United

#### States
(continued)

Elanco

Animal

Health,

Inc. \*

†

143,156

$

2,044,268

Eli

Lilly

&

Co.

145,367

113,317,937

Jazz

Pharmaceuticals

PLC \*

26,826

2,846,775

Johnson

&

Johnson

400,702

61,207,230

McKesson

Corp.

39,377

28,854,678

Merck

&

Co.,

Inc.

451,193

35,716,438

Organon

&

Co. †

107,451

1,040,126

Perrigo

Co.

PLC

47,112

1,258,833

Pfizer,

Inc.

1,154,439

27,983,601

Viatris,

Inc.

446,849

3,990,362

Zoetis,

Inc.

169,909

26,497,308

384,516,724

#### Total

#### Common

#### Stocks
(Cost:

$681,484,159)

607,736,796

#### SHORT-TERM

#### INVESTMENT

#### HELD

#### AS

#### COLLATERAL

#### FOR

#### SECURITIES

#### ON

#### LOAN:

#### 2.6%

#### Money

#### Market

#### Fund:

#### 2.6%
(Cost:

$15,771,761)

State

Street

Navigator

Securities

Lending

Government

Money

Market

Portfolio

15,771,761

15,771,761

#### Total

#### Investments:

#### 102.1%
(Cost:

$697,255,920)

623,508,557

#### Liabilities

#### in

#### excess

#### of

#### other

#### assets:

#### (2.1)%
(13,047,422)

#### NET

#### ASSETS:

#### 100.0%
$

610,461,135

#### Definitions:
ADR

American

Depositary

Receipt

\*

Non-income

producing

†

Security

fully

or

partially

on

loan.

Total

market

value

of

securities

on

loan

is

$56,264,637.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VanEck ETF Trust

- **b. Investment Company Act file number:** 811-10325

- **c. CIK number of Registrant:** 0001137360

- **d. LEI of Registrant:** 549300ZLFKNTXC51ZN76

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 666 THIRD AVENUE, 9TH FLOOR

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 212-293-2000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VanEck Pharmaceutical ETF

- **b. EDGAR series identifier (if any):** S000034409

- **c. LEI of Series:** 5493008SDOYUHMC8LF44

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-09-30

- **b. Date as of which information is reported:** 2025-06-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $630764685.10

**Total Liabilities:** $15906124.35

**Net Assets:** $614858560.75

**Cash Not Reported:** $888083.00

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000105867 | -1.12%               | -1.67%               | -0.07%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $7308030.57              | $-12379506.54                              |
| Month 2  | $2699949.09              | $-17846838.28                              |
| Month 3  | $-13187762.99            | $11263541.04                               |

### Schedule of Portfolio Investments

| Name                               | Title                                                                       | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Viatris Inc                        | Viatris Inc                                                                 | CUSIP: 92556V106<br>LEI: 254900ZZTSW7NL773X71 | Long             | EC               | CORP              | US        |    450084 | NS      | $4019250.12   | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                  | Johnson & Johnson                                                           | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    403603 | NS      | $61650358.25  | 10.03%            |  |  |  | No            |                  1 | On Loan: No      |
| Bausch Health Cos Inc              | Bausch Health Cos Inc                                                       | CUSIP: 071734107<br>LEI: B3BS7ACMDUWISF18KY76 | Long             | EC               | CORP              | CA        |    132176 | NS      | $880292.16    | 0.14%             |  |  |  | No            |                  1 | On Loan: —       |
| AbbVie Inc                         | AbbVie Inc                                                                  | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    148637 | NS      | $27589999.94  | 4.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Takeda Pharmaceutical Co Ltd       | Takeda Pharmaceutical Co Ltd                                                | CUSIP: 874060205<br>LEI: 549300ZLMVP4X0OGR454 | Long             | EC               | CORP              | JP        |   1185341 | NS      | $18325371.86  | 2.98%             |  |  |  | No            |                  1 | On Loan: —       |
| State Street Global Advisors       | State Street Navigator Securities Lending Government Money Market Portfolio | CUSIP: 857509301<br>LEI: 5493008BJIBKQ5KTIF74 | Long             | STIV             | RF                | US        |  15704041 | NS      | $15704041.00  | 2.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Zoetis Inc                         | Zoetis Inc                                                                  | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    171139 | NS      | $26689127.05  | 4.34%             |  |  |  | No            |                  1 | On Loan: No      |
| GSK PLC                            | GSK PLC                                                                     | CUSIP: 37733W204<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |    683928 | NS      | $26262835.20  | 4.27%             |  |  |  | No            |                  1 | On Loan: —       |
| Novo Nordisk A/S                   | Novo Nordisk A/S                                                            | CUSIP: 670100205<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    673435 | NS      | $46480483.70  | 7.56%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                    | AstraZeneca PLC                                                             | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    386022 | NS      | $26975217.36  | 4.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc            | Axsome Therapeutics Inc                                                     | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     16451 | NS      | $1717319.89   | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Perrigo Co PLC                     | Perrigo Co PLC                                                              | CUSIP: 000000000<br>LEI: 549300IFOQS6R1QLY196 | Long             | EC               | CORP              | IE        |     47453 | NS      | $1267944.16   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi SA                          | Sanofi SA                                                                   | CUSIP: 80105N105<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |    572743 | NS      | $27669214.33  | 4.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Organon & Co                       | Organon & Co                                                                | CUSIP: 68622V106<br>LEI: 549300AMCKY57OK2CO56 | Long             | EC               | CORP              | US        |    108229 | NS      | $1047656.72   | 0.17%             |  |  |  | No            |                  1 | On Loan: —       |
| Pfizer Inc                         | Pfizer Inc                                                                  | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |   1162796 | NS      | $28186175.04  | 4.58%             |  |  |  | No            |                  1 | On Loan: No      |
| Jazz Pharmaceuticals PLC           | Jazz Pharmaceuticals PLC                                                    | CUSIP: 000000000<br>LEI: 635400GAUMJCLEZRRV50 | Long             | EC               | CORP              | IE        |     27020 | NS      | $2867362.40   | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora Inc                        | Cencora Inc                                                                 | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |     79639 | NS      | $23879754.15  | 3.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Haleon PLC                         | Haleon PLC                                                                  | CUSIP: 405552100<br>LEI: 549300PSB3WWEODCUP19 | Long             | EC               | CORP              | GB        |   2169686 | NS      | $22499643.82  | 3.66%             |  |  |  | No            |                  1 | On Loan: —       |
| McKesson Corp                      | McKesson Corp                                                               | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     39662 | NS      | $29063520.36  | 4.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries Ltd                                          | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |    584350 | NS      | $9793706.00   | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Elanco Animal Health Inc           | Elanco Animal Health Inc                                                    | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |    144192 | NS      | $2059061.76   | 0.33%             |  |  |  | No            |                  1 | On Loan: —       |
| Novartis AG                        | Novartis AG                                                                 | CUSIP: 66987V109<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |    386988 | NS      | $46829417.88  | 7.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                     | Merck & Co Inc                                                              | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    454459 | NS      | $35974974.44  | 5.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                     | Eli Lilly & Co                                                              | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    146419 | NS      | $114138003.07 | 18.56%            |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co            | Bristol-Myers Squibb Co                                                     | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    567488 | NS      | $26269019.52  | 4.27%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-07-30

**Name of Applicant:** VanEck ETF Trust

**Signature:** James Parker

**Name of Signer:** James Parker

**Title:** Assistant Treasurer